Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: Association with clinical characteristics and outcome

Annals of Oncology

Volumn 14, Issue 3, 2003, Pages 467-474

  Terol, M J ^a   Tormo, M ^a   Martinez Climent, J A ^a   Marugan, I ^a   Benet, I ^a   Ferrandez, A ^a   Teruel, A ^a   Ferrer, R ^b   Garcia Conde J ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL FRANCESC DE BORJA   (Spain)

Author keywords

Diffuse large B cell lymphoma; Prognosis; Soluble intercellular adhesion molecule 1 (CD54)

Indexed keywords

ANTHRACYCLINE; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERCELLULAR ADHESION MOLECULE 1; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANK SUM TEST; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERCELLULAR ADHESION MOLECULE-1; L-LACTATE DEHYDROGENASE; LYMPHATIC METASTASIS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0037348545     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg057     Document Type: Article

References (36)

1. Malgoba MW, Sanders ME, Ginther Luce GE et al. ICAM-1: a ligand for LFA-1 dependent adhesion of B, T and myeloid cells. Nature 1988; 331: 86-88.
2. Voraberger G, Schafer R, Stratowa C. Cloning of the human gene for intercellular adhesion molecule-1 and analysis of its 5′-regulatory region. Induction by cytokines and phorbol ester. J Immunol 1991; 147: 2777-2786.
3. Kuhlman P, Moy VT, Lollo BA, Brian AA. The accessory function of murine ICAM-1 in T lymphocyte activation. Contributions of adhesion and co-activation. J Immunol 1991; 146: 1773-1782.
4. Wawryck SO, Novotny JR, Wicks IP et al. The role of LFA-1/ICAM-1 interaction in human leukocyte homing and adhesion. Immunol Rev 1989; 108: 135-161.
5. Momosaki S, Yano H, Ogasawara S et al. Expression of intercellular adhesion molecule 1 in human hepatocellular carcinoma. Hepatology 1995; 22: 1708-1713.
6. Johnson JP, Stade BG, Holzmann B et al. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 1989; 86: 641-644.
7. Tomita Y, Watanabe H, Kobayashi H et al. Expression of intercellular adhesion molecule-1 on transitional cell cancer. Am J Pathol 1993; 143: 191-198.
8. Horst E, Radaszkiewicz T, Hofftman-den Otter A et al. Expression of the leukocyte integrin LFA-1 (CD11a/CD18) and its ligand ICAM-1 (CD54) in lymphoid malignancies is related to lineage derivation and stage of differentiation but not to tumor grade. Leukemia 1991; 5: 848-853.
9. Boyd AW, Dunn SM, Fecondo JV et al. Regulation of expression of a human intercellular adhesion molecule (ICAM-1) during lymphohematopoietic differentiation. Blood 1989; 73: 1896-1903.
10. Cavallo F, Martin-Fontecha A, Bellone M et al. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 1995; 25: 1154-1162.
11. Terol MJ, López-Guillermo A, Bosch F et al. Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. J Clin Oncol 1998; 16: 35-40.
12. Stopeck AT, Gessner A, Miller TP et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 2000; 6: 3904-3909.
13. Christiansen I, Gidlöf C, Wallgren AC et al. Serum levels of soluble intercellular adhesion molecule-1 are increased in chronic B-lymphocyte leukemia and correlate with clinical stage and prognostic markers. Blood 1994; 84: 3010-3016
14. Christiansen I, Gidlöf C, Kälkner KM et al. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumor burden, disease activity and other prognostic markers. Br J Haematol 1996; 92: 639-646.
15. Christiansen I, Enblad G, Kälkner KM et al. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival. Leuk Lymphoma 1995; 19: 243-251.
16. The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
17. Rodriguez J, Cabanillas F, McLaughlin et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the tumor score. Ann Oncol 1992; 3: 711-717.
18. Cabanillas F, Rodriguez-Diaz Pavon J, Hagemeister FB et al. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma. Ann Oncol 1998; 9: 511-518.
19. Kaplan GL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
20. 2/E in the log-rank test for survival data or tumor incidence data. Biometrics 1973; 29: 759-784.
21. Cox DR. Regression model and life tables. J R Stat Assoc 1972; 34: 187-220.
22. Miller TP, Grogan TM, Dahlberg S et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-1466.
23. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-251.
24. Niitsu N, Iijima K. High serum soluble CD44 is correlated with a poor outcome aggressive non-Hodgkin's lymphoma. Leuk Res 2002; 26: 241-248.
25. Stauder R, Greil R, Schultz TF et al. Expression of leukocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin's lymphoma and leukemias: possible influence on growth pattern and leukaemic behaviour. Clin Exp Immunol 1989; 77: 234-238.
26. Perez-Encinas M, Quintas A, Bendana A et al. Correlation and prognostic value of serum soluble ICAM-1, beta-1 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 33: 551-558.
27. Harabuchi Y, Kataura A, Imai K. Circulation intercellular adhesion molecule-1 and its cellular expression in head and neck non-Hodgkin's lymphomas, including lethal midline granuloma. Ann Otol Rhinol Laryngol 1996; 105: 634-642.
28. Lei KI, Johnson PJ. The prognostic significance of serum levels of soluble intercellular adhesion molecule-1 in patients with primary extranodal non-Hodgkin's lymphoma. Cancer 2000; 89: 1387-1395.
29. Tacyildiz N, Yavuz G, Gozdasoglu S et al. Serum levels and differential expression of intercellular adhesion molecule-1 in childhood leukemia and malignant lymphoma: prognostic importance and relationship with survival. Pediatr Hematol Oncol 1999; 16: 149-158.
30. Conconi A, Zucca E, Roggero E et al. Prognostic models for diffuse large B-cell lymphoma. Hematol Oncol 2000; 18: 61-73.
31. Mounier N, Morel P, Haioun C et al. A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de L'Adulte. Cancer 1998; 82: 1952-1962.
32. Dumontet C, Mounier N, Munck JN et al. Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. Br J Haematol 2002; 118: 210-217.
33. Hazlehurst LA, Damiano JS, Buyuksal I et al. Adhesion to fibronectin via beta 1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19: 4319-4327.
34. Lagneaux L, Delforge A, Bron D et al. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91: 2387-2396.
35. De la Fuente MT, Casanova B, García-Gila M et al. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B-cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999; 13: 266-274.
36. Fornarini B, D'ambrosio C, Natoli C et al. Adhesion to 90K (mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood 2000; 96: 3282-3285.